I-Mab has entered a strategic partnership with Kalbe Genexine Biologics, a joint venture of Kalbe Farma Tbk and Genexine, Inc. KG Bio will receive a right of first negotiation for an exclusive license for the commercialization of two I-Mab discovered product candidates: TJD5, a highly differentiated anti-CD73 antibody in Phase 1 development for advanced solid tumors, and an I-Mab product candidate to be agreed upon.

KG Bio will have a right of first negotiation for exclusive rights to commercialize these two product candidates in certain Asian and Middle-East regions. If I-Mab and KG Bio enter into the definitive licensing agreement for TJD5, I-Mab would be eligible to receive as much as approximately $340 million from KG Bio, including an upfront payment and subsequent development and commercial milestones, as well as royalties.

“This partnership recognizes the potential of our internally-discovered anti-CD73 antibody TJD5 in immuno-oncology, and its clear clinical differentiation related to a novel epitope of CD73,” said Dr. Jingwu Zang, Founder, Honorary Chairman and Director of I-Mab. “We are pleased to enter into this strategic partnership with the Kalbe corporate family, which is a leader in commercializing innovative therapies in Southeast Asia and other key strategic markets and deepen our relationship with Genexine. We believe this partnership will expand the commercialization potential of TJD5 and other candidates in our portfolio.”